| Name | Title | Contact Details |
|---|
Northeast Dental is a Rochester, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
In 2011, Viva Naturals was founded by a team of people who didn`t just know a lot about wellness—they made it their way of life. And nothing has changed since: from the reception desk to the boardroom, everyone at Viva believes in the power of healthy living (and the power of a good laugh, because it`s not healthy to take yourself too seriously). As wellness enthusiasts, we take pride in putting out the caliber of product we`d want for ourselves.
The Federation of American Hospitals (FAH), founded in 1966, is the national representative of investor-owned or managed community hospitals and health systems throughout the United States and one of Washington, DC`s most respected and influential health policy and advocacy organizations. Dedicated to a market-based philosophy, we provide representation and advocacy on behalf of our members to Congress, the Executive Branch, the judiciary, media, academia, accrediting organizations and the public. The Federation of American Hospitals serves its members as a clearinghouse for information about the nation`s most vital health policy issues. These include Medicare and Medicaid, the uninsured, health care quality, patient safety, health information technology, medical liability insurance reform, rural health care, long-term hospital care, inpatient psychiatric care, hospital emergency preparedness, antitrust, compliance, the health care workforce shortage, privacy and confidentiality, tax issues, and rehabilitation services, among other important issues.
Surface Oncology is a clinical-stage immuno-oncology company focused on using its specialized knowledge of the biological pathways critical to the immunosuppressive tumor microenvironment (TME) for the development of next-generation therapies to help patients suffering with cancer. Recent advances in understanding how the immune system fights cancer has created a first wave of immunotherapies with profound benefits for some patients. These first-generation therapies, or "checkpoint inhibitors", have been groundbreaking, but only a relatively small subset of patients is deriving long-term benefit. We believe that the lack of a broad and sustained clinical response is because these first-generation therapies only target one component of the immunosuppressive TME and a broader, more multi-faceted therapeutic approach is required. We are a team on a mission to deliver transformative outcomes for people with cancer by breaking through the frontiers of immuno-oncology research. Our diverse clinical and preclinical pipeline of immune-enhancing antibody candidates target the innate and adaptive arms of the immune system to deliver dramatically different therapies for patients and their families. Surface is leveraging its deep understanding of TME biology to target factors and cells that suppress patients’ anti-tumor immune response. Our broad attack on the TME has the potential to convert patients’ non-responsive ‘cold’ tumors into immune-active ones. We push ourselves to break through across all dimensions of our work. From a discovery perspective, Surface leverages its world-class SAB to identify new targets and takes an aggressive approach towards generating diverse, highly-specific antibodies, which allows our scientists to thoroughly explore the relevant biology. Our antibody discovery approach generates therapeutic-quality antibodies, as well as unique tools to explore the biology of the tumor microenvironment.
First Continental International (NJ) is a Rochelle Park, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.